ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

MREO vs DWTX // RSI-14 & 200D SMA MOMENTUM

Mereo BioPharma Group plc (NASDAQ) VS. Dogwood Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: MREO 1 — DWTX 2
▲ RSI-14 & 200D SMA MOMENTUM LEADER: DWTX
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (MREO VS. DWTX) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC MREO DWTX SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% -32.30% -2.70 DWTX /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield — — — TIE /fcf-yield <GO>
Operating Margin -60.00% — — TIE /operating-margins <GO>
Net Profit Margin 68.00% — — TIE /net-margins <GO>
Revenue Growth (YoY) — — — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity — — — TIE /balance-sheet <GO>
Piotroski F-Score Quality 2/9 2/9 0.00 TIE /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum ACTIVE 43.7 45.3 -1.60 DWTX /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $46.2M $43.5M $2.7M MREO /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR MREO REV DWTX REV MREO GROSS % DWTX GROSS % MREO FCF DWTX FCF
FY 2025 $500.0K $78.3M — — -$31.0M -$15.6M
FY 2024 $132.6M $34.2M — — -$32.8M -$8.8M
FY 2023 $10.0M $15.3M — — -$21.1M -$4.9M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
MREO // BETA —
DWTX // BETA —